Universtiy of Colorado Hospital
Aurora, Colorado, 80045, United States
Location status: Recruiting
Location contact
Inga Cuba Research Manager
CONTACT
Raj Shah, MD
PRINCIPAL_INVESTIGATOR
Sandra Boimbo DART Program Director
CONTACT
NCT Number: NCT07120295
This study plans to enroll up to 75 research subject who have a biliary disorder such as bile duct stones or intermediate biliary strictures. The purpose of this research is to assess whether the Dragonfly™ Pancreaticobiliary Scope functioned as intended in combination with the commercially available accessories during your scheduled endoscopy procedure. This includes achieving stone fragmentation of difficult biliary stone(s) while obtaining adequate tissue specimens for analysis. There will also be a Product performance evaluation as rated by the endoscopist operating the DPS System and evaluation of ergonomics and usability.
Interested in participating?
Request Info21 year and older
All sexes
Interventional
Phase 4
Aurora, Colorado, 80045, United States
Location status: Recruiting
Inga Cuba Research Manager
CONTACT
Raj Shah, MD
PRINCIPAL_INVESTIGATOR
Sandra Boimbo DART Program Director
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dragonfly™ Digital Pancreaticobiliary System is indicated for use in the direct visualization of the biliary and pancreatic ducts for diagnostic and therapeutic interventions during endoscopic procedures. DPS is a single-use device that serves as an access and delivery catheter used with a proprietary DDC. The DDC is intended to control auto-illumination, and process images from the DPS for diagnostic and therapeutic applications during endoscopic procedures in the pancreaticobiliary system including the hepatic ducts.
Time frame: Up to 6 months
Will evaluate the effectiveness of digital cholangioscopy (DC) in guiding fragmentation of difficult biliary stones. Will examine the efficacy of the intraductal lithotripsy procedure utilizing electrohydraulic lithotripsy in achieving biliary stone fragmentation and complete bile duct stone clearance among patients who have failed conventional stone extraction techniques. Stone fragmentation and complete ductal clearance will be assessed using descriptive statistics with interquartile range (IQR) for the number of procedures to achieve clearance at index or subsequent procedures. Ninety-five percent confidence intervals will be provided for descriptive statistics.
Time frame: Up to 6 months
Will evaluate the ability of the DC to deliver tools to obtain adequate tissue samples (biopsies) to be analyzed for the presence or absence of disease, including cancer, infection, or other conditions in subjects with indeterminate strictures. Will use descriptive analysis with sensitivity, specificity, accuracy, median and IQR plus operating characteristics of visualization and sampling in those patients with indeterminate strictures. Will evaluate the diagnostic efficacy of the novel biopsy forceps in the context of indeterminate biliary strictures and provide robust evidence for clinical decision-making.
Time frame: Up to 6 months
Will evaluate the total procedure time for bile duct stones.
Time frame: Up to 6 months
Will evaluate the number of procedures required to achieve bile duct stone clearance after referral. Will summarize with descriptive statistics and report success rates. Ninety-five percent confidence intervals will be provided for descriptive statistics.
Time frame: Up to 6 months
Will assess whether the DPS functioned as intended in combination with the commercially available accessories. Functioned as intended is defined as the ability to set up, provide visualization, deliver the accessory to the target location, use of the accessory according to the instructions for use. Will summarize with descriptive statistics and report success rates.
Time frame: Up to 6 months
Will evaluate ergonomics by collecting anthropometric data from physician users. Will provide product performance evaluation data.
Time frame: Up to 6 months
Will evaluate lithotripsy fragmentation time for bile duct stones. Will summarize with descriptive statistics and report success rates.
Time frame: Up to 6 months
Will evaluate product performance for indeterminate biliary strictures as rated by the endoscopist operating the DPS system. Will summarize with descriptive statistics and report success rates.
Time frame: At the completion of the study
Will assess usability by the System Usability Scale. Will provide product performance evaluation data.
Time frame: Up to 6 months
Will evaluate the ability to adequately visualize biliary strictures, including the presence of both neoplastic (irregular nodular mucosa, irregular papillary projections, intraductal or villous mass, dilated and tortuous vessels with branching, infiltrative stricture, ulceration, and contact friability/ease of oozing) and benign (concentric, bandlike scar, uniform projections, thin vessels) characteristics. Will summarize with descriptive statistics and report success rates.
Time frame: Up to 6 months
Will evaluate usability by the ability to visualize stone or stricture characteristics as rated by the endoscopist operating the DPS system.
Time frame: At the completion of the study
Will assess user satisfaction with the Net Promoter Score. Will provide product performance evaluation data.
Time frame: Up to 6 months
Will evaluate usability by the ability to pass the lithotripsy device and/or stone removal device to the target area as rated by the endoscopist operating the DPS system.
Time frame: After each case
Will assess the subjective assessment of work by the National Aeronautics and Space Administration-Task
Time frame: At 6 months
Will evaluate the bile duct stone recurrence rate. Will summarize with descriptive statistics and report success rates.
Contact information is provided by the study sponsor or research team.
University of Colorado, Denver
Other
Prospective Multicenter Clinical Performance Study of a Single-use Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04042831
Bile Duct Adenocarcinoma, Bile Duct Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT06715839
Appendiceal Neoplasms, Appendix Cancer
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07025174
Adenocarcinoma, Bile Duct Carcinoma
Hangzhou, Zhejiang, China
View Trial DetailsNCT07729917
Adenocarcinoma, Bile Duct Carcinoma
Hangzhou, Zhejiang, China
View Trial Details